| Title: |
MM-355 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study |
| Authors: |
Sonneveld, Pieter, Moreau, Philippe, Dimopoulos, Meletios A., Quach, Hang, Ho, P. Joy, Beksac, Meral, Hulin, Cyrille, Antonioli, Elisabetta, Leleu, Xavier, Mangiacavalli, Silvia, Perrot, Aurore, Cavo, Michele, Belotti, Angelo, Broijl, Annemiek, Gay, Francesca, Mina, Roberto, Nijhof, Inger S., van de Donk, Niels W.C.J., Katodritou, Eirini, Schjesvold, Fredrik, Sureda Balari, Anna, Rosiñol, Laura, Cavo, Michel, Roeloffzen, Wilfried, Driessen, Christoph, Vangsted, Annette, Einsele, Hermann, Spencer, Andrew, Hajek, Roman, Jurczyszyn, Artur, Lonergan, Sarah, Liu, Yanfang, Wang, Jianping, Vieyra, Diego, van Brummelen, Emilie M.J., Vanquickelberghe, Veronique, de Boer, Carla J., Carson, Robin, Bladé, Joan, Boccadoro, Mario, Rodriguez-Otero, Paula |
| Source: |
In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S550-S551 |
| Database: |
ScienceDirect |
